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Abstract 
Introduction 
Our understanding of the involvement of the immune system in cancer control has increased 
over recent years. However, the development of cancer vaccines intended to reverse tumor-
induced immune tolerance remains slow as most current vaccine candidates exhibit limited 
clinical efficacy. The skin is particularly rich with multiple subsets of dendritic cells (DCs) that 
are involved to varying degrees in the induction of robust immune responses. Transcutaneous 
administration of cancer vaccines may therefore harness the immune potential of these DCs, 
however, this approach is hampered by the impermeability of the stratum corneum. Innovative 
vaccine formulations including various nanoparticles, such as liposomes, are therefore needed 
to properly deliver cancer vaccine components to skin DCs. 
Areas covered 
The recent insights into skin DC subsets and their functional specialization, the potential of 
nanoparticle-based vaccines in transcutaneous cancer vaccination and, finally, the most 
relevant clinical trial advances in liposomal and in cutaneous cancer vaccines will be discussed. 
Expert commentary 
To define the optimal conditions for mounting protective skin DC-induced anti-tumor immune 
responses, investigation of the cellular and molecular interplay that controls tumor progression 
should be pursued in parallel with clinical development. The resulting knowledge will then be 
translated into improved cancer vaccines that better target the most appropriate immune 
players. 
Keywords: Cancer vaccine, liposome, nanoparticle, skin dendritic cell, transcutaneous 
vaccination.  
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1. Introduction 
The last decades have witnessed a gradual shift in cancer management from conventional 
therapy (surgery, radiation therapy, chemotherapy and endocrine therapy) to immunotherapy, 
mainly with monoclonal antibodies specific for tumor antigens. More recently, targeted 
immunotherapies, intended to break the immune tolerance induced by tumors or to actively 
stimulate the patient’s immune system against cancer cells, have emerged. These approaches 
stem from our understanding that despite being antigenic and often also immunogenic, most 
tumors fail to induce protective immunity because of their immunosuppressive 
microenvironment. Immunotherapy is therefore intended to reverse this microenvironment 
effect, thus harnessing the immune system to attack cancer cells.   
 
2. Cancer immunity: challenges and vaccine design requirements 
2.1. Protective tumor-specific immune response 
A protective adaptive immune response against tumor cells should consist of several key steps, 
including 1) Tumor Associated Antigen (TAA) expression by tumor cells, and release of these 
antigens by dying cells. 2) Release of amage associated molecular patterns (DAMPs) that 
provide danger signals to dendritic cells (DCs) inducing their maturation. DAMPs are recognized 
by specific receptors on DCs named Pattern Recognition Receptors (PRR). 3) Cross-presentation 
of tumor antigens by mature DCs, on MHC class I and class II molecules, to tumor-specific CD8+ 
and CD4+ T cells respectively. 4) Priming of tumor-specific T cells resulting in cytotoxic T 
lymphocyte (CTL) differentiation. 5) Migration of effector T cells and infiltration of the tumor 
and, finally, 6) recognition and killing of tumor cells by effector CTLs. Optimal CTL 
differentiation requires, in addition to mature DCs, the presence of CD4+ IFN-γ-producing T 
helper cells, named Th1 (figure 1).  
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2.2. Kinetics of tumor development and escape from immune response 
During the initial tumor development stage, the tumor-specific immune response is capable of 
eliminating all immunogenic cancer cells. Progressively, mutations decrease tumor cell 
immunogenicity resulting in a dynamic “equilibrium phase”, where the immune system cannot 
destroy all cancer cells, but only most of them, to keep the cancer in a dormant state. This state 
will progressively fade, as specific tumor escape mechanisms, along with the exhaustion of 
lymphocytes, will render this immune response inefficient. At this stage, the balance between 
the effector and regulatory immune compartments is seriously broken and the tumor enters 
the “evasion phase” and develops more rapidly [1]. 
Tumor escape mechanisms were divided by Teng et al (2015) [2] into three major categories 
(table 1). First, under the selective pressure of the immune system, a myriad of genetic and 
epigenetic alterations occurs, resulting in several events referred to as immunoediting. They 
include inhibition of antigen presenting machinery, expression of new TAAs, and 
downregulation or loss of highly immunogenic TAAs and co-stimulatory molecules. Second, 
tumor cells survival and resistance to apoptosis and to cytotoxic effectors of immunity is 
enhanced. Third, tumors establish an immunosuppressive microenvironment by favoring the 
induction and recruitment of immunosuppressive cells such as regulatory T cells (Tregs) and 
myeloid-derived suppressor cells (MDSC). Therefore, the pattern of tumor infiltrating 
lymphocyte subsets is a key criterion that drives disease progression. 
 In addition, chronic antigen exposure causes a continuous ligation of inhibitory receptors on 
immune effector cells. This leads to an “exhausted” [2], characterized by Wherry et al as “a 
poor effector function, a sustained expression of inhibitory receptors and a transcriptional state 
distinct from that of functional effector or memory T cells” [3]. Under normal physiological 
conditions, the immunosuppressive pathways described above are crucial for the prevention of 
excessive immune responses and thus, the maintenance of self-tolerance by ensuring a balance 
between inhibitory and co-stimulatory signaling. In the case of cancer, however, these 
mechanisms shift the balance towards an inhibitory state [2]. 
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2.3. Therapies based on reversal of immune tolerance  
In theory, in order to reverse tumor-induced immune tolerance, the above-mentioned key 
steps can be targeted using two different therapeutic approaches. On one hand, administration 
of antagonists of inhibitory signals or agonists of co-stimulatory ones can be used to inhibit 
immunosuppressive mechanisms and amplify antigen-specific T cell responses. On the other 
hand, therapeutic cancer vaccines are intended to induce active cancer immunity either by 
activating pre-existing host antitumor immune cells or by inducing the differentiation of new 
ones.  
Cancer vaccines are therapeutic preparations intended to enhance both the number and the 
function of tumor-specific CTLs. They should therefore contain CD8+ T cell epitopes derived 
from TAA of the targeted tumor type, as well as CD4+ T cell epitopes and a potent adjuvant. 
Mutated tumor neoantigens, which arise from point mutations that cause frameshifts resulting 
in new peptides, are among the most antigenic TAAs. Therefore, they are promising candidates 
for cancer vaccines. The adjuvant, which is usually a PRR ligand, plays the role of a danger signal 
that activates and drives maturation of DCs. Following uptake and epitope cross-presentation, 
mature DCs would induce Th cells and tumor-specific CTLs. Besides its composition, the delivery 
route of the vaccine is also crucial as it dictates the amount and type of DCs to be targeted. It 
may also contribute to vaccine-induced inflammation that plays a role in DC maturation. 
The most popular vaccination routes are the intramuscular (IM) and the subcutaneous (SC) 
ones, mainly for their ease of administration, despite the scarcity of DCs in muscles and their 
virtual absence in the hypodermis. Recently, the transcutaneous approach has been considered 
because of the abundance of DCs in the skin.  
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3. Vaccination via the skin  
3.1. The skin immune system 
The skin is the main barrier that protects the body from the external environment, and 
therefore, is continuously challenged by microbes, physical and chemical aggressions and 
injuries. To face these challenges, it harbors a specialized, highly complex innate and adaptive 
immune network, capable of mounting adequate immune responses. This ‘skin immune 
system’ (SIS) consists of specialized skin-resident immune cells, along with immunocompetent 
skin-trophic lymphocytes and DCs that constantly recirculate between the skin, the lymphatic 
vessels, the skin-draining lymph nodes and, in the case of lymphocytes, the bloodstream. 
In many species, including humans and mice, the skin is anatomically composed of 3 layers, 
namely, from the outer to the inner side, the epidermis, the dermis and the hypodermis. The 
epidermis is comprised mainly of keratinocytes. Its outermost layer is the stratum corneum, or 
horny layer, which is composed of 4-20 layers of dead corneocytes and largely contributes the 
barrier function of the skin. The immune cells of the epidermis are Langerhans cells (LCs) and 
effector and memory CD8+ cytotoxic T cells. The dermis is a connective tissue composed of a 
fibroblast-rich network of collagen and elastin fibers embedded in proteoglycans, providing 
strength and elasticity to the skin [4]. It contains dermal dendritic cells (dDCs), natural killer 
(NK) cells, memory B and T cells as well as mast cells and macrophages [4,5]. The hypodermis is 
also called the subcutaneous (SC) tissue or adipose tissue. This layer of white fat is composed 
mainly of fibroblasts and adipocytes and plays a role in fat reserve and thermal isolation. Unlike 
the epidermis or the dermis, the hypodermis naturally lacks resident immune cells [4]. Finally, 
the skin contains appendages like hair follicles and sebaceous glands that together, form 
pilosebaceous units. Hair follicles originate from the dermis, are surrounded by an epidermal 
sheath [4] and are connected with a network of blood capillaries and nerve endings. The 
epidermal sheath surrounding the follicle is a stratified epithelium that is continuous with the 
epidermis. However, it is discontinued at the entrance of the sebaceous gland duct to the hair 
canal [6]. Thus, hair follicles represent a potential entry port for pathogens and chemicals 
(figure 2). 
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3.2. Skin DCs subsets 
The skin contains a large number of DCs. These immune sentinels exhibit potent phagocytic, 
macropinocytic and endocytic activity, thereby internalizing microorganisms, cell debris, 
pathogen constituents and soluble molecules from their surroundings. Their role is to 
constantly sample their microenvironment, process antigens and present them to T 
lymphocytes. 
3.2.1. Langerhans  cells 
LCs are the only DC subset in the epidermis, accounting for 2-5% of all epidermal cells [4,7]. 
They are characterized by a high expression of langerin (CD207) and MHC class II, an 
intermediate expression of CD11b (CD11bint) and the absence of the integrin alpha E chain 
(CD103-) [8]. Overall, 2–3 % of LCs circulate naturally and continuously from the epidermis to 
the lymph nodes, across the dermis [4].  
LCs are specialized in epidermal immunosurveillance. Despite their scarcity, their extensive 
network of dendrites covers the epidermis entirely and extends and retracts in a rhythmic 
manner allowing them to sample the fluid in the intercellular spaces between keratinocytes 
[7,9]. This behavior is termed ‘‘dendrite surveillance extension and retraction cycling habitude’’ 
(dSEARCH) [7]. Activated LCs can migrate to draining lymph nodes to prime antigen-specific T 
lymphocytes, thus initiating humoral and cellular immunity. 
Additionally, upon sensing inflammatory signals, they can provide skin surface 
immunosurveillance by increasing their dSEARCH motion and projecting their dendrites through 
tight junctions between keratinocytes towards the stratum corneum [9]. Thereby, they are able 
to collect pathogens/particles that have not yet breached the epidermal barrier. Ouchi et al [10] 
have shown that after patch immunization of mice with S. aureus-derived toxin, a high 
molecular weight molecule unable to cross the stratum corneum barrier, a protective IgG1 
antibody response was detectable in their sera. Similarly, confocal microscopy experiments 
performed on immunostained human epidermal sheets, showed that the dendrites of activated 
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LCs, extend above the tight junctions [9], and internalize topically applied proteins via 
endocytosis. 
Whether LCs are capable of immunosurveillance of the dermis is still debatable. Using a mouse 
model of dermal melanocytosis, Hemmi et al. suggested that epidermal LCs could not reach 
down to the dermis as they failed to uptake melanocyte granules [11]. However, more recently, 
Flacher et al. showed that monoclonal antibodies (mAb) targeting endocytic receptors were 
efficiently taken up by LCs in human and mouse skin explants [12]. Moreover, using in vivo 
experiments, they showed that these monoclonal antibodies are subsequently transported by 
LCs to the draining lymph nodes [13]. To explain these results, two scenarios can be proposed. 
It is most probable that the mAb have diffused across the basement membrane separating 
dermis and epidermis. Yet, it cannot be excluded that LCs have reached “down” to the dermis 
where they internalized them.  
3.2.2. Dermal dendritic cells 
Dermal DCs (dDCs) are heterogeneous. Their markers vary between mice and humans. In 2005, 
Kissenpfennig et al showed [14] that langerin/CD207, first thought to be restricted to LCs, was 
also expressed by some dDCs subpopulations. Based on the expression of CD207, CD11b and 
CD103, Henri et al [8] identified in 2010 four distinct sub-populations of DCs from digested skin: 
CD207high CD11bint CD103- cells corresponds to the epidermal LCs “en route” towards lymph 
nodes, while the three remaining subsets are dermal resident subsets, including CD207+ 
CD11blow CD103+, CD207-CD11b+ CD103- and CD207- CD11b- CD103-. 
Similar to LCs, dDCs are all MHCIIhigh. They can present antigens to T cells following uptake, 
maturation and migration to draining lymph nodes. Dermal DCs were shown to carry 
Leishmania major antigens [15] or locally applied ovalbumin antigens [16] to draining lymph 
nodes, where they induced antigen-specific T cell proliferation. 
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3.3. Antigen presentation potential of skin DCs 
3.3.1. Endocytic receptors of skin DCs 
Skin DCs are equipped with a panel of receptors that mediate pathogen/vaccine uptake and 
tailor vaccine-induced immune responses [17]. Among these, endocytic receptors of the C-type 
lectin superfamily recognize pathogen-specific carbohydrate structures. They therefore offer 
the opportunity of targeting the endocytic pathway via their specific ligands. Examples of 
endocytic receptors are DC-SIGN/CD209, Langerin/CD207, Clec9A/DNGR and the mannose 
receptors family, including the mannose receptor MR/CD206, DEC-205/CD205, Endo180, and 
the M-type phospholipase A2 receptor [18]. 
3.3.2. Skin DC function in cellular immune response activation: relevance to cancer 
vaccination? 
Protective immunity against cancer cells requires cross-presentation of exogenous antigenic 
peptides on both MHC class I and class II to CD8+ and CD4+ T cells respectively, in order to drive 
CTL differentiation. While it is established that under inflammatory conditions, both LCs and 
dDCs have the ability to induce a specific immune response against foreign pathogens, their 
selective capacity in initiating and driving cancer-specific immune response is largely debated 
(Table 2).  
Early studies suggested that only LCs were capable of cross-presentation. LCs differentiated in 
vitro from human CD34+ hematopoietic progenitors were shown to sample necrotic/apoptotic 
melanoma cells and efficiently prime CD8+ T cells thereby generating melanoma-specific CTLs 
[19]. In another study, LCs that were induced to migrate from the epidermis in the presence of 
external stimuli had the ability to cross-present both soluble and cell-bound protein antigens on 
their MHC class I molecules and to induce CTLs capable of killing antigen-loaded cells [12,20]. In 
D
ow
nl
oa
de
d 
by
 [A
us
tra
lia
n C
ath
oli
c U
niv
ers
ity
] a
t 0
4:2
1 2
3 S
ep
tem
be
r 2
01
7 
Ac
ce
pte
d M
an
us
cri
pt
10 
 
vivo, it was reported that both intradermal and transcutaneous immunization resulted in CD8+ T 
cell proliferation in draining lymph nodes [20,21]. 
On the other hand, LCs are believed to play an immunoregulatory role to promote tolerance 
and prevent excessive inflammation. For example, they were shown to constitutively promote 
local proliferation and activation of skin resident memory CD4+ regulatory T cells (Treg) and to 
migrate to skin-draining lymph nodes where they present self-antigens to T cells [22,23]. 
Moreover, the depletion of LCs in a mouse model of contact hypersensitivity resulted in a 
higher number of antigen-specific effector T cells, without affecting the Treg count [24]. 
Regarding dDCs, recent reports suggested that langerin+  CD103+ dDCs are particularly potent in 
terms of cross-presenting antigens to CD8+ T cells [8,25]. Other dDC subpopulations, on the 
other hand, fail to cross-present endogenous and viral antigens [8,25] and seem to mediate 
mostly CD4+ T cell priming [25]. It should be noted, however, that cross-presenting langerin+  
CD103+ dDCs represent a very small population (2.6%) of dDCs [26]. 
Another level of complexity was revealed when it was found that targeting a given C-type lectin 
receptor does not invariably generate the same type of immune response in different DCs; 
similarly, within the same DC population, signaling via different C-type lectin receptors may 
lead to different outcomes. For example, early works suggested that targeting either DEC-
205/CD205 or langerin/CD207 results in efficient cross-presentation and proliferation of CD4+ 
and CD8+ T cells [21]. However, newer results indicated that these two receptors might not be 
similarly involved in antigen presentation, depending on the DC subset that captures the 
targeting antibody. Indeed, LCs targeted through DEC-205/CD205 seem to perform cross-
presentation and promote CD8+ T cell proliferation [12,27], while those targeted through 
langerin rather tolerize CD8+ T cells for the antigen [12,26]. Conversely, antigen capture by 
langerin+ CD103+ dDCs via either langerin of DEC-205 consistently leads to potent CD8+ T-cell 
responses [12,26]. Further exploration of methods allowing selective targeting and stimulation 
of LCs and dDCs is needed to achieve the most appropriate cross-presentation of vaccine 
antigens. 
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Altogether, the current findings of skin immunobiology have so far proven the 
undeniable skin potential of mounting immune responses. The various, often controversial 
reports underline the skin DCs ability in driving the immune response either toward an 
immunostimulatory or an immunoregulatory state, depending on specific conditions (type and 
dose of antigen, danger signals, targeting receptor). This highlights not only the flexibility of the 
skin-induced immune responses, but also the high specialization and cooperation between 
different skin DC subsets. Further understanding of their activation conditions and their 
respective contribution in T cell priming and CTL induction is still needed for the development 
of improved skin-delivered vaccines. 
4. Strategies of transcutaneous vaccination 
4.1. Transcutaneous vaccination: making skin DCs the main vaccine recipients 
Cutaneous vaccine delivery routes are distinguished as subcutaneous when the injection targets 
the hypodermis, intradermal when the vaccine is delivered within the dermis and 
transcutaneous (TC) when it is applied on the epidermis. Although subcutaneous injections are 
widely used with acceptable results, this route ensures only suboptimal delivery of vaccines 
since the hypodermis is naturally devoid of skin-resident DCs (LCs and dDCs). Therefore, direct 
delivery of antigen to these cells appears as a potentially more efficient, alternative for cancer 
vaccination. Since intradermal vaccination does not favour uptake by LCs, the TC route is worth 
investigating. However, despite its promising potential, it is hampered by the stratum corneum, 
the impermeable outermost skin layer. The ultimate goal of TC vaccination is to ensure non-
invasive antigen delivery through this barrier to the targeted DCs in the internal skin layers. 
4.2. Barrier role of the stratum corneum 
The stratum corneum exhibits highly selective permeability dictated by the size and lipophilicity 
of applied molecules. Depending on these parameters, TC passage of the vaccine molecules 
implies their uptake through multiple ports of entry that can be, either transepidermal, 
comprising the intercellular and the transcellular routes, or transfollicular (Figure 3 (a)).  
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For the transepidermal passage, only molecules smaller than 500 Daltons have a chance to 
cross the stratum corneum and reach internal skin layers [28]. The intercellular way is the most 
predominant route for transepidermal passage, especially for small uncharged, relatively 
lipophilic, molecules. However, small highly hydrophilic molecules and specific peptides, known 
as cell-penetrating peptides, were reported to cross the epidermis via the intracellular route 
[29–32]. 
  
The stratum corneum is composed of keratin-rich dead corneocytes embedded in a lipid matrix 
[33]. In normal conditions, the fluid fraction is minimal and both lipids and keratin are solid, 
resulting in skin impermeability and elasticity. An increase in the fluid fraction can yield to mild 
transient permeabilization of the stratum corneum towards polar and apolar compounds. 
Achieving a hydration gradient can be performed by increasing the proportion of natural skin 
moisturizing factors (e.g. urea, glycerol) [34], by skin hydration prior to immunization or by 
applying occlusive bandage after vaccination. Once internalized, vaccine molecules diffuse 
toward the higher hydration gradient presented by the circulation under the epidermis. 
The transfollicular route contributes largely and in different ways to TC crossing. The epithelium 
of the hair follicle infundibulum is immature, permitting the passage of soluble antigens [35] and 
selective entry of small particles [36]. Hair follicles have a reservoir function, however, they 
occupy less than 0.1% of the total skin surface, and their density varies considerably according 
to body sites and individuals [35]. Besides, all hair follicles are not available for particles 
penetration: only “active” hair follicles are “open” for transfollicular passage, as hair growth 
and/or sebum production ensure removal of plugs formed by shed corneocytes and excess 
sebum [6]. 
4.3. Physical barrier disruption 
The physical properties of classical vaccines are usually not adapted for the TC route. In recent 
years, several barrier-disrupting and permeation-enhancing strategies have been developed, in 
addition to innovative vaccine formulations. Two types of strategies are currently used for 
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stratum corneum barrier disruption: the first one relies on removal of one or more layers prior 
to vaccine application and the second relies on driving the vaccine components through the 
stratum corneum (Table 3).  
Sandpapering, skin waxing and skin surface stripping are widely used to remove hair, excess 
sebum and a few layers of the stratum corneum [38,39] (Figure 3 (b)). Skin surface stripping was 
tested in preclinical trials and in humans to promote antigen penetration through the 
transepidermal or the transfollicular route. The technique resulted in an improvement in the 
immunogenicity of applied vaccines [4,37,47], but was uncomfortable to the patient. An 
alternative cyanoacrylate skin surface stripping procedure on human skin [48] proved to be 
more efficient and less uncomfortable.  
Techniques using an external driving force include sonoporation, electroporation and thermal 
poration to transiently and locally disrupt the stratum corneum, or the use of jet injectors and 
micro-/nano-needles to deposit the vaccine directly inside the live skin layers (Figure 3 (b)). 
Recent reports on preclinical trials of cancer transcutaneous vaccination using microneedles 
have shown promising results. For instance, in mice, two microneedle-delivered cancer vaccines 
were capable to induce humoral and cytotoxic responses and to slow tumor growth upon 
challenge. The first is a DNA vaccine for cervical cancer [49], while the second is a 
microparticulate vaccine based on a whole cell lysate of a murine ovarian cancer cell line [50].  
 
4.4. Innovative vaccine formulations for skin barrier crossing 
To enable TC antigen delivery, another attractive strategy relies on the vaccine formulation 
itself.  
4.4.1. Peptide-based vaccines combined to adjuvants 
The current trend with vaccine design is to replace whole microorganism-based vaccines that 
are often toxic and reactogenic with proteins or even small synthetic peptides. Given their small 
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size, these vaccines offer the additional advantage of being more suitable for the TC route. 
However, unlike whole microorganism-based vaccines, they are devoid of Microbe Associated 
Molecular Patterns (MAMPs) that provide danger signals to PRRs. Therefore, they are poorly 
immunogenic and require the co-administation of adjuvants to provide these signals and induce 
DC maturation. Classical adjuvants come in the form of emulsions (such as MF59 and 
Incomplete Freund’s adjuvant, termed montanide when it is clinical grade) or colloids (such 
aluminum hydroxide called alum and aluminum phosphate). When they are injected, this 
physical form of results in a depot effect that ensures slow release of the vaccine components 
at the administration site, thereby increasing their uptake and presentation to DCs. Moreover, 
Alum induce danger signal by targeting the NALP3 PRR [51]. However, emulsions and colloids 
are not suitable for TC administration since they are unable to cross the cutaneous barrier [51]. 
Alternative modern adjuvants are pathogen-derived components, chosen to function as 
MAMPs, like lipopeptides, recombinant proteins and nucleic acid sequences.  
4.4.2. Nanoparticles for transcutaneous immuniz tion 
Nanoparticles are well known for their capacity to permeate the skin and mediate delivery of 
compounds of different sizes and polarities, therefore, their use has become a popular strategy 
for TC vaccine delivery. Nanoparticles can effectively co-deliver the needed adjuvant along with 
the vaccine antigen(s), and they improve the stability of the vaccine by protecting it from the 
external environment and ensure its controlled slow release at the delivery site. Moreover, 
their formulation techniques are flexible allowing addition of the needed adjuvant and of 
various “ligand” molecules on their surface for targeted delivery. Their size and zeta potential 
can be modified for optimal transdermal passage, uptake by DCs and subsequent immune 
response.  
“Nanoparticles” (NP) designate matricial as well as vesicular colloidal systems. Matricial systems 
are nanospheres made of a matrix of polymers or of solid lipid(s), where the active compounds 
are interspersed. Immunostimulating Complexes (ISCOMs) are one of the most successful 
examples. These are spherical cage-like particles, approximately 30-40 nm in diameter, made of 
cholesterol, phospholipids and glycosides (Quill A saponins), with a potent adjuvant property. 
Vesicular systems can also be made of polymers or lipids (the bi-layered lipid vesicles liposomes 
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for example) but they have an inner liquid (aqueous or lipid) core. Active components can be 
incorporated either in their core or in the surrounding layer(s), or they can be attached or 
adsorbed on their surface (figure 4).  
 
4.4.3. Physicochemical properties influencing nanoparticles interaction with the skin 
immune system 
Size. Nanoparticle size is a critical parameter that does not only largely predict TC passage, but 
also uptake by DCs and lymphatic draining efficiency. It was reported that the upper limit for 
intact skin absorption was 20 nm, while barrier-disrupted skin allows passage of nanoparticles 
up to 50 nm in diameter [52,53] and even 200 nm for ultradeformable ones [54]. Interestingly, 
the optimal particle size for transfollicullar passage was reported to be in the 600 nm range, 
allowing the highest penetration depth [55] (figure 5). 
Nanoparticles ranging from 40 to 200 nm are optimal for fast and efficient uptake by DCs 
[56,57], including LCs [58]. Such virus-sized particles enter cells either by receptor-mediated 
endocytosis into clathrin-coated pits (<150nm), or through caveolae (50-80 nm). Particles 500-
5000 nm, considered to be bacteria-like in size, are preferentially taken up by macrophages 
instead of DCs, through phagocytosis [56] (figure 5). 
Nanoparticles were shown to enhance the efficacy of anticancer vaccines by ensuring targeted 
delivery of tumor antigen and adjuvant to lymph node-resident antigen presenting cells, 
following intradermal injection [59]. Nanoparticles ranging from 10 to 100 nm seem to be most 
optimal for lymphatic draining. They can efficiently drain to regional lymph nodes while being 
sufficiently retained in the vaccination site, thereby increasing the chance of antigen uptake 
and presentation by DCs  [60]. Within this range, particles of 20 nm and 45 nm diameter seem 
to be the most efficient for lymphatic draining [61]. Indeed, particles of 100 nm diameter were 
found to be 10 times less efficient of those of 25 nm diameter in lymphatic transport and 
accumulation in lymph nodes [62]. Large particles (>500 nm diameter) are very poorly drained 
to lymph nodes, whereas small ones (<10 nm) diffuse so rapidly that their chance to encounter 
DCs is minimized [60] (figure 5). 
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An in vivo study conducted by Fifis et al showed that among intradermally injected polystyrene 
nanoparticles ranging from 20 nm to 2000 nm, optimal immunogenicity was achieved by those 
in the viral size range of 40-50nm [63]. A closer assessment of the influence of minute 
differences in nanoparticle size showed that intradermal administration of 40-49 nm 
nanobeads activates IFN-γ secreting CD8+ T cells, while that of 93-123 nm ones induces a CD4+ T 
cell response and IL-4 [64] (figure 5). These findings underline the influence of the particle size 
on the cytokine profile and the type of elicited immune response, which may be of particular 
importance in the case of transcutaneous vaccination against cancer that requires CD8+ T cell 
activation and IFN-γ secretion. 
Charge. The nanoparticle surface charge, reflected by its zeta potential, can largely affect its 
capacity to penetrate the skin. As the skin is negatively charged, it is expected to be more 
efficiently crossed by cationic or neutral nanoparticles. Indeed, such nanoparticles, like 
liposomes, were found to be more efficient in drug delivery into deep skin layers [65]. However, 
Kohli et al reported that only negatively charged latex particles could permeate through the 
skin. This unexpected finding was attributed to their passage via channels created by the 
repulsive forces between them and negatively charged skin lipids [52]. 
When it comes to internalization into DCs, it was demonstrated that charge is only important 
for larger particles: 1 µm polystyrene particles were more efficiently taken up when positively 
charged, while for those < 500 nm, the degree of internalization is independent of the surface 
charge [57,66]. 
How surface charge affects the induced immune response is still debatable. Nakanishi et al 
reported that protein antigens encapsulated into cationic liposomes are best delivered to APC 
cytosol and loaded on MHC class I, thus eliciting a cellular immune response [67]. Alternatively, 
Cui and Mumper showed that anionic chitosan-based nanoparticles induce higher antibody 
titers and cytokine production than cationic ones [68]. 
It is undeniable that these basic intrinsic properties can influence to a large extent nanoparticle 
penetration into the skin, their uptake by DCs and their immune activation properties. 
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Nevertheless, current available data does not make it yet reasonable to draw final conclusions. 
Additionally, initial nanoparticle properties may not be sufficient to predict their behavior in 
vivo since they may be altered by their interaction with the skin lipids or with physiological 
fluids: nanoparticles can possibly aggregate to the micron-scale, their charge may change, etc. 
Smart nanoparticle systems. These nanoparticles are designed to be applied through the 
transfollicular route and to release their active components only upon specific stimuli in order 
to increase follicular penetration of vaccine molecules. For example, bovine serum albumin 
nanoparticles encapsulating active compounds can be applied simultaneously with protease. 
Their subsequent enzymatic degradation ensures protease-triggered controlled release of their 
content [69]. 
4.4.4. Potential of liposomes for transcutaneous immunization 
Liposomes were the first nanoparticles to be developed, about 40 years ago, and they remain 
the most investigated ones. They are the subject of a high number of patents and are available 
on the market as vectors of vaccines [70–72] and transcutaneously delivered drugs [73,74]. 
These are nanometric vesicles, composed of natural or synthetic biodegradable, cholesterol 
containing, phospholipid bilayers surrounding an aqueous core. Their zeta potential is defined 
by the nature of their phospholipids. Their structure allows them to transport both hydrophilic 
substances encapsulated in their core, and hydrophobic ones integrated in their lipid bilayers. 
Because their composition is closely related to that of biological membranes, they are highly 
tolerable and bear low intrinsic pro-inflammatory activity and are therefore among the most 
attractive nanoparticles for vaccination [75]. Liposomes provide passive targeting of skin DCs. 
Indeed, they are rapidly internalized by surrounding cells, ensuring a sufficient amount of 
vaccine is collected by the DCs, while “non-packaged” vaccines are less stable and risk rapid 
draining of their components.  
Efficacy of liposomal carriers in TC crossing has been established since 1980, when they were 
used for the first time for topical drug delivery [76]. In this study, they were shown to achieve a 
four- to five-fold increase of the drug concentration in the epidermis and the dermis, as 
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compared to drug alone. Subsequent studies have however proposed their relatively rigid 
structure to be suboptimal for skin penetration. Liposomes were thus proposed to enhance 
drug deposition only in the upper layers of the stratum corneum, without reaching the internal 
living layers [77]. Because of their unique versatility in composition and size, liposomes are 
actively investigated as vehicles for TC vaccination. To increase skin penetration, many variants 
have been developed including transfersomes and ethosomes. 
The term “transfersomes” was introduced for the first time by Cevc and Blume in 1992 [78] and 
is a trademark of IDEA AG, Munich, Germany. They are ultradeformable liposomes made with 
small unsaturated soybean lecithin and an edge activator, usually a surfactant. They are able to 
squeeze into pores much smaller than their size and to carry a remarkable amount of lipid into 
the skin. Therefore, they were expected to enhance cutaneous vaccine delivery through the 
stratum corneum with minimal barrier disruption [79]. For instance, Wang et al. found that 
cationic ultradeformable liposomes delivering HBs antigen DNA by the TC route induce potent 
cellular and humoral immune responses that were superior to those induced by conventional 
liposomes, and comparable to intramuscular injection of naked DNA [80]. Additionally, Gupta et 
al found that transfersomes induce higher anti-TT titers as compared to conventional liposomes 
[81]. Similarly, transdermal immunization with ultradeformable liposomes was reported to 
induce stronger cellular and humoral immunity against merozoite surface protein-1 (PfMSP-
119) of Plasmodium falciparum, as compared to conventional liposomes [82]. However, 
contradictory results about the transfersome’s increased potential as compared to 
conventional liposomes can also be found [32,83]. 
Ethosomes are obtained by adding a high percentage of ethanol (up to 45%) to conventional 
liposomes, thus significantly increasing their fluidity [83]. Rattanpack et al reported them to be 
the most efficient vesicular carriers. It is also possible to combine ethanol and surfactants in a 
single nanoparticle to maximize the fluidity enhancement effect. The resulting vesicles are 
called transethosomes [54,84]. 
4.4.5. Adapting nanoparticles for adequate skin DC targeting 
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In order to benefit from the skin potential in mounting protective immune responses following 
TC vaccination with nanoparticles, these particles should be able to reach, target and activate 
the most appropriate skin DCs (epidermal LCs and/or dDCs) that would induce Th1 and CTL 
responses. Targeting nanoparticles to receptors expressed on skin DCs improves the interaction 
between them. Espuelas et al. showed that adding a mannose residue to liposomes enhanced 
their uptake by human DCs through mannose receptor-mediated endocytosis [85]. When 
mannosylated liposomal cancer vaccines were injected SC in tumor-bearing mice, it was 
possible to decrease the adjuvant dose up to 100-fold without any loss in the anti-tumoral 
efficiency [86]. Translation of this strategy would be particularly interesting in TC vaccination 
where the minimal amount of vaccine that crosses the stratum corneum barrier would be 
compensated by a higher uptake by skin DCs. 
5. Transcutaneous cancer vaccination using nanoparticles: where do we stand? 
To date, the search by keywords “cancer vaccine” yields to more than 1800 returns in the 
National Institute of Health database for clinical trials (www.clinicaltrials.gov). Out of these, 185 
studies (10%) are in phase 3 and only two therapeutic cancer vaccines, Sipuleucel-T (Provenge®) 
[87] and talimogene laherparepvec (IMLYGIC, Amgen, Inc.) [88], have been licensed for clinical 
use. These numbers underline not only the great efforts that are being dedicated to cancer 
vaccine research, but also the challenges faced in the development of such vaccines. Despite 
their extensive diversity (purified peptides, proteins, antigen-loaded autologous DCs, 
nanoparticle-based vaccines, etc), all of these vaccines are required to elicit specific CD4+ cells 
and  protective CTL responses. In addition, some were designed to also induce humoral 
responses. Various administration routes have been applied in clinical trials. While most 
vaccines are delivered subcutaneously [89–96] a few are delivered intradermally [97–99]. A 
combination of both routes has also been tested and is known as intracutaneous [100,101]. 
However, cancer TC vaccination in humans has rarely been tested [102] and never with 
nanoparticle-based vaccines (Tables 4 and 5). 
5.1. Nanoparticle-based cancer vaccines in development 
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Various nanoparticles like nanoemulsions, polymeric and magnetite nanoparticles, ISCOMs and 
liposomes have shown efficacy in vaccine preclinical trials, but only the ISCOMs and liposomes 
have reached clinical studies.  
5.1.1. ISCOM-based cancer vaccines 
ISCOMs were first used to deliver viral and bacterial antigens. The promising results prompted 
the development of ISCOM-based antitumoral vaccines. The cage-like matrix of ISCOM 
nanoparticles is designated as ISCOMATRIX. An ISCOM-based cancer vaccine specific for NY-
ESO-1 has been tested in clinical trials. NY-ESO-1 is a cancer-testis antigen expressed in normal 
testis but also in tumors of various tissues, including melanoma and ovarian cancer. In a phase I 
clinical trial involving patients with resected melanoma, it elicited NY-ESO-1-specific antibody 
responses, CD4+ and CD8+ T cells [92] and persistent memory [94]. In a phase II clinical trial 
conducted on advanced metastatic melanoma patients, antibody responses were confirmed, 
however patients  
failed to develop cellular immunity and had no clinical benefits [95]. In an attempt to increase 
the NY-ESO-1 specific CD8+ T cell response, this vaccine was combined to a recombinant NY-
ESO-1 fowlpox virus in a heterologous prime-boost strategy.  In a phase I clinical trial, it gave 
positive CD8+ T cell responses in 3/18 patients [96]. 
5.1.2. Liposome-based cancer vaccines 
Cancer liposomal vaccines have been extensively used in preclinical studies where they have 
shown variable efficacy. A vaccine was developed against hepatocellular carcinoma. It bears a 
peptide derived from Glypican-3 (GPC3), a TAA overexpressed in this type of cancer. Although 
devoid of an adjuvant molecule, this vaccine resulted in an inhibition of tumor growth [103]. 
Another vaccine expressing murine ErbB2-derived peptide and incorporating the TLR4 ligand 
Monophosphoryl lipid A (MPLA) was evaluated in mice. Subcutaneous injection of this vaccine 
resulted in the induction of a CTL response, yet, showed only partial protection against ErbB2-
expressing tumors [104]. We have designed a peptide-anchoring liposome-based vaccine 
expressing a human ErbB2-derived CD8+ T cell epitope, a universal CD4+ T cell epitope and, 
dipalmitoyil alanyl cysteine glycine (Pam2CAG), a potent TLR2/6 ligand. This vaccine was 
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evaluated in a mouse model bearing transgenic murine renal carcinoma cells expressing the 
human ErbB2 protein. It induced a specific immune response against the ErbB2 peptide and 
exhibited an efficient antitumoral effect after subcutaneous injection [86] and needle-free 
airway administration [105,106]. 
One of the most promising liposome-based formulations that proved to be efficient in 
preclinical trials was developed by Immunovaccine (Halifax, Canada) under the name of 
VacciMax®.  This vaccine-enhancement platform consists of a water-in-oil emulsion in which 
liposomes are emulsified in Incomplete Freund's adjuvant. A more stable, water-free, 
generation of VacciMax, called Depovax® (DPX) was developed for clinical trials. It consists of 
lyophilized liposomes re-suspended in montanide immediately prior to vaccination [107]. DPX-
0907, one of the variants of Depovax®, contains a TLR ligand, a universal Th peptide derived 
from tetanus toxoid, as well as seven human leukocyte antigen (HLA)-A2 restricted peptides 
derived from various TAAs. These peptides are specifically presented by MHC class I on breast, 
ovarian, and prostate cancer cells [89]. A phase I clinical trial of DPX-0907 increased the 
frequency of CD8+ T cells in advanced-stage breast, ovarian and prostate cancer patients, with 
61% immunological response rate and induced antigen-specific T cell memory [90]. This clinical 
trial provides a rationale for further evaluation of the clinical benefits of DPX-0907, especially in 
breast and ovarian cancer subjects. It is to be noted however, that the integrity of the 
liposomes when suspended in a mineral oil such as montanide may have been affected and the 
clinical benefit of this formulation cannot therefore be attributed with certainty to the 
liposome formulation or to the adjuvant itself. 
BLP25 or tecemotide, also known as Stimuvax®, is another promising liposomal anti-cancer 
vaccine that has reached late clinical stages. It consists of a multilamellar liposome 
incorporating a TLR4 ligand (MPLA), and BP25, a peptide derived of the mucin 1 (MUC1) 
protein. MUC1 is a TAA overexpressed in more than 90% of adenocarcinomas including breast 
and lung cancers. BP25 contains CD4+ and CD8+T cell epitopes. Phase I and II trials conducted on 
non-small-cell lung cancer patients showed tolerability, induction of MUC1-specific T-cell 
proliferation and cytokine production as well as extended median survival [91]. However, in a 
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randomized phase III trial designated START (Stimulating Targeted Antigenic Responses to 
NSCLC), BLP25 alone did not provide any significant survival benefit. Nonetheless, it was shown 
to be beneficial for patients treated with concurrent chemotherapy by providing a 10.2 months 
extension of overall survival [108]. An additional 20 months median follow-up time confirmed 
these findings [93]. 
5.2. Transcutaneous cancer vaccines in clinical trials 
In the vast majority of cancer vaccine trials involving the cutaneous route, antigen 
administration is performed either subcutaneously or intradermally, while the adjuvant is 
applied topically. The goal of this strategy is to deliver sufficient amounts of the antigen in the 
dermis and simultaneously activate LCs in the epidermis by the adjuvant. 
This combination protocol was first used for a melanoma vaccine based on full length NY-ESO-1 
protein. In a phase I clinical trial where non emulsified NY-ESO-1 was injected ID, and 
imiquimod, a TLR7 agonist was applied TC, a specific humoral response was elicited, however, 
this vaccine failed to induce a CD8+ T cell response [99]. An improved vaccine in which NY-ESO-1 
protein was emulsified in montanide and imiquimod was replaced with resiquimod, a related 
more potent TLR7/8 agonist, resulted in a potent humoral immune response and a CD8+ T cell 
response was induced in 3/12 patients [98].  
CDX-1401, another NY-ESO-1 based vaccine, is composed of the full length NY-ESO-1 protein 
fused to a human mAb targeting the DEC-205 receptor expressed on DCs. It was tested in a 
phase I clinical trial in 45 patients with diverse advanced malignancies, in combination with 
various TLR ligands (Resiquimod targeting TLR7/8 and poly-ICLC targeting TLR 3), both by the SC 
and the TC routes. Persistent cellular immunity and clinical benefits were observed in 56% and 
29% of the patients respectively, distributed to all study cohorts, independently of the 
administration route [101]. 
As of today, only one clinical trial was conducted on a cancer vaccine administered exclusively 
through the TC route. This vaccine consisted of a mixture of melanoma-derived peptides 
dissolved in DMSO (Dimethylsulfoxide). Melanoma patients were vaccinated TC after skin 
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barrier disruption by tape stripping. The vaccine provided an overall survival of 55.8 months for 
patients who responded to all vaccine peptides, compared to 20.3 months for partial 
responders [102].  
These studies provide evidence of the efficiency of skin DCs in inducing tumor-specific CD8+ T 
cell responses when they are activated under the appropriate conditions and an additional 
rationale for the use of the TC route for cancer vaccination. Future studies will likely explore 
more closely the exact factors that drive optimal immune responses against topically applied 
vaccines and uncover more potent adjuvant molecules that can better amplify tumor-specific 
CTL responses. 
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6. Conclusion 
The key to successful cancer immunization resides in appropriate activation of DCs capable of 
reversing the tumor-induced immune tolerance. The skin has a unique and potent immune 
network, especially rich with DCs capable of inducing and tailoring immune responses. Skin DCs 
have shown a potential for driving tumor-specific immune responses in mouse models and in 
humans. Needle-free, nanoparticle-mediated, transcutaneous delivery of cancer vaccines is 
therefore intended to target skin DCs including LCs and dDCs, in order to improve tumor-
specific immune response amplitude and quality. Several strategies acting on the level of the 
vaccine formulation (carrier, adjuvant, DC targeting molecules …) and on the TC vaccination 
techniques (tape stripping, microneedles …) have been developed to overcome the stratum 
corneum barrier. A careful combination of these strategies is expected to drive the 
development of next generation cancer vaccines.  
 
7. Expert commentary 
Cancer vaccination is far more challenging than microbial vaccination. While microbes express a 
large panel of MAMPs and antigens that are strong activators of innate and adaptive immunity, 
cancer cells express mostly self-antigens. TAAs are generally poorly immunogenic. Additionally, 
within a single tumor, cancer cells may have different TAA expression profiles and exhibit 
different escape mechanisms. Consequently, despite decades of efforts, cancer vaccination has 
not yet reached its golden age. The major challenge is therefore to induce a protective immune 
response against carefully selected TAA peptides properly presented by adequate DCs.  Only 
two cancer vaccines are currently in clinical use.   
On the other hand, recent efforts have focused on harnessing the antigen presentation 
potential of skin DCs. Several strategies have been developed to overcome the barrier of the 
stratum corneum, including the use of nanoparticles. Encouraging results reported in clinical 
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trials of intradermal administration of a virosomal influenza vaccine are good proof of the 
feasibility of this approach. 
Unfortunately, our knowledge of skin immunobiology is still incomplete. A large number of 
studies have been conducted, but their experimental settings varied extensively, thereby 
leading to contradictory results. For instance, the respective roles of LCs and dDC 
subpopulations in immune activation are far from being elucidated: the first studies suggested 
that LCs were the only players in antigen cross-presentation, but later, it was found that 
CD207/Lang+ dDC are also involved. Therefore, this role remains to be attributed to one or the 
other or both populations.  
Our knowledge about the ideal nanoparticles properties for TC vaccination is also limited. We 
need better investigation of the influence of nanoparticles physicochemical characteristics (size, 
charge, and composition) on skin barrier crossing, targeting a d activation of adequate antigen 
presenting cells. Reported studies have used a large variety of models: nanoparticles were 
tested either in vivo or on human or porcine skin explants that may be frozen/thawed or fresh. 
These tests lead obviously to non-coherent, often contradictive results.  
The high number of variables should therefore be counterbalanced by the establishment of 
common study design or, better, by organizing the laboratories into consortia. Centralization of 
generated data is expected to elucidate the networks of cellular cooperation that arise between 
these cells and identify optimal nanoparticle properties for specific targeting of the desired DC 
subpopulation. 
Another challenge resides in the choice of molecules to be incorporated in the nanoparticles. 
Indeed, single epitope vaccination approaches are MHC dependent and would be effective only 
in a subpopulation of cancer patients expressing the appropriate HLA genotype. Therefore, 
multi-epitope vaccines might be more adequate. Moreover, when the selected epitopes are 
derived from multiple TAAs, they decrease the risk of emergence of vaccine resistance 
following TAA dowregulation by tumor cells.  This argues for the need for additional profiling of 
different malignancies, in order to identify the most relevant TAA peptides in each cancer type. 
D
ow
nl
oa
de
d 
by
 [A
us
tra
lia
n C
ath
oli
c U
niv
ers
ity
] a
t 0
4:2
1 2
3 S
ep
tem
be
r 2
01
7 
Ac
ce
pte
d M
an
us
cri
pt
26 
 
Further studies are also needed to identify optimal targeting and adjuvant molecules to 
improve uptake and activation of DCs.  
Finally, there is a need to improve the reproducibility of transcutaneous vaccination techniques. 
Current practices may lead to variable results between individuals depending on the zone, size 
and hair follicle density of the application site. Development of transcutaneous vaccination 
devices that help standardizing the process deserves further attention.  
For all these reasons, it will be many years before transcutaneous cancer vaccination unleashes 
its full potential. The half way target that currently seems the most reachable is the local 
treatment of melanomas, because lymphocytes primed by skin-derived DCs express skin 
homing receptors and are sufficiently recruited to the vaccination site. Additionally, 
combinatorial therapeutics, whether exclusively immunological, such as TC cancer vaccines and 
immune checkpoint inhibitors, or mixed immunological-chemical, such as TC cancer vaccines 
with concomitant chemotherapy, seem to be equally promising on the short-term. 
8. Five-year view 
This review of cancer vaccination strategies that are currently being investigated highlights the 
exponential growth of our understanding in the recent years. Important discoveries have been 
made in different converging fields, including tumor biology (TAA expression, escape 
mechanisms), cancer specific immunity (immune checkpoints, antigen presentation), 
vaccinology (adjuvantation, nanoparticles and cell targeting) as well as skin immune potential 
(LC, dDC). They are expected to progressively bridge the gap in knowledge regarding optimal TC 
cancer vaccine formulations and skin DC targeting strategies. As the respective roles of skin DC 
subpopulations will be better understood, appropriate ways of targeting them through 
nanoparticles and targeting molecules will be optimized. Identification of new adjuvants 
adapted to TC delivery will further improve vaccine efficacy. 
 
Many clinical trials are already in the pipeline, with the most advanced being for melanoma 
treatment. Obviously, in the case of melanoma, topical application of the vaccine directly on 
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the cancer lesion is expected to induce local protective immunity, but this is not the only 
intended effect. Indeed, similar to the currently used intratumoral melanoma vaccine (T-VEC), 
TC melanoma vaccines are expected to induce also systemic immunity, leading to the 
regression of metastatic lesions distant from the vaccination site. If such findings are confirmed, 
they will strongly encourage the application of TC vaccination to other kinds of tumors.   
Finally, it will be interesting to evaluate in clinical trials the addition of TC vaccines to currently 
validated therapies based on immune checkpoint modulators and/chemotherapeutic drugs.  
Their purpose would be to tip the balance from immune tolerance of tumors toward tumor 
rejection. 
 
9. Key issues  
• Cancers escape the immune system through many mechanisms, including 
immunoediting.  Despite the potential immunogenicity of tumor cells, protective 
immune responses are rarely elicited and the balance is tipped towards tumor 
tolerance, thus favoring cancer aggressiveness and progression.     
• To restore efficient immune rejection, cancer vaccines must re-educate the immune 
system to overcome tumor-induced tolerance.  
• The skin harbors a complex network of dendritic cells. Langerhans cells and 
CD207+/Langerin+ dermal dendritic cells are thought to be potent inducers of CTL 
responses which are crucial for tumor specific immunity. Targeting these dendritic cells 
is possible through the transcutaneous route, if the vaccine can cross the impermeable 
stratum corneum barrier. 
• Several strategies were recently developed to allow vaccine formulations to overcome 
the stratum corneum barrier. They include the incorporation of vaccine components 
into nanoparticles and the disruption of the skin barrier by microneedles and other 
means.   
• Research is currently focusing on determining critical nanoparticle properties, such as 
size, charge and composition, for optimal delivery to skin dendritic cells and uptake.  
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Because of their versatility and their similarity with biological membranes, liposomes 
are among the most promising nanoparticles adapted for transcutaneous immunization.  
• In liposome-based vaccines, antigenic molecules can be incorporated into the liposome 
or expressed on its surface.  Adapted adjuvants that are suitable for skin barrier crossing 
can be added.  Additionally, it is possible to insert, in the liposome surface, DC targeting 
molecules whose receptors are differentially expressed on skin DC subsets. This strategy 
allows the delivery of a greater vaccine cargo to the desired cells. Sometimes, these 
receptors can also have an immunostimulatory role.  
• Recently, several clinical trials have translated preclinical findings into human testing. 
Liposome-based vaccines are under current clinical investigation by classical routes. On 
the other hand, peptide-based vaccines are being investigated by the TC route. A 
combination of the key elements of these success stories is expected to drive TC cancer 
vaccination using liposomal peptide vaccines into clinical development. 
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Table 2: Role of skin DCs in immune activation. 
Cell type Phenotypic 
markers 
Role in cellular immunity Reference 
Langerhans cells 
CD207 high 
CD11bint 
CD103- 
In vitro and in vivo induction of T 
cell proliferation 
 
Induction of antigen-loaded cells 
killing by CD8+ T cells  
[14,22,23] 
 
[22] 
Dermal dendritic 
cells 
CD207+ 
CD11blow 
CD103- CD207+ dDCs are particularly 
potent in inducing a CD8+ response [15] CD207+ 
CD11blow 
CD103+ 
CD207-  
CD11b+  
CD103- 
Induction of a CD4+ T cell response [15] 
CD207-  
CD11b- 
CD103- 
Int: intermediate 
 
Table 3: Skin barrier disruption techniques. 
Physical barrier 
disruption technique Process Properties References 
Abrasion, waxing, 
skin surface 
stripping 
Removal of stratum corneum 
Improve the immunogenicity 
of applied vaccines 
Uncomfortable when a high 
number of strikes is needed 
[4,37–39] 
 
Jet injectors 
Skin piercing with 
compressed gas hitting the 
skin with high velocity 
Delivery of liquid or powder 
vaccines  
May cause pain, bruising, and 
application-site burning 
[40,41] 
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Microneedles 
Hollow or vaccine-coated 
solid or dissolvable needles 
Painless and Self-administered [42–44] 
Thermal 
microporation or 
thermal ablation 
Stratum corneum 
vaporization with highly 
focused thermal energy. 
Induction of micron-sized 
pores. 
Delivery of hydrophilic molecules 
Induce activation and migration 
of LCs 
[37,45] 
Sonoporation/ 
electroporation 
Transient molecular-scale 
disruption of the cellular 
plasma membrane 
Expensive and needs a power 
supply 
[37,41] 
Permeation 
enhancers, addition 
of polar chains, 
conjugation to cell 
penetrating 
peptides 
Molecular interactions with 
plasma membranes 
Increase the permeability to 
macromolecules 
[31,46] 
 
Table 4: Examples of the most promising cancer vaccines involving lipid-based carriers. 
Vesicle 
type Vaccine Adjuvant 
Administratio
n route 
Traget 
cancer 
type 
Clinica
l trial Study outcome REF  
Liposom
e 
Depovax 
(DPX)-0907: 
7 TAA-
derived Tc 
peptides, 
and a 
tetanus 
toxoid-
derived Th 
epitope 
Polynucleotid
e based-
adjuvant 
SC Breast, 
ovarian, 
prostate 
cancer 
Phase 
I 
- Specific CD8+ 
T cell 
response 
(61% 
response 
rate) 
- Specific T 
cell memory 
[82]
BLP-25 , or 
Tecemotide, 
or Stimuvax 
: BP 25 
peptide of 
the MUC1 
protein 
MPLA (TLR 4 
agonist) 
SC Non-
small-cell 
lung 
cancer 
Phase 
III 
- MUC1 
proliferative 
T cell 
response  
- No survival 
benefits, 
unless with 
concurrent 
[83,85,100
] 
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chemothera
oy 
ISCOM NY-ESO-1 
ISCOMATRI
X : Full 
length NY-
ESO-1 
protein 
ISCOM 
vesicles 
SC Melanom
a 
Phase 
II 
- High titer 
NY-ESO-1 
antibodies  
- Circulating 
specific 
CD4+ and 
CD8+ cells 
- Response 
persistence 
for 252-1155 
days  
- Absence of 
delayed 
hypersensiti
vity  
- No clinical 
benefits 
[84,86,87]
Full length 
NY-ESO-1 
protein, and 
a 
recombinan
t fowlpox 
virus 
Recombinant 
fowlpox virus  
IM
(prime boost 
protocol) 
Melanom
a 
- - CD8+ T cell 
response in 
3/18 
patients 
[88]
TAA: tumor-associated antigen; HLA: human leucocyte antigen; SC: subcutaneous; MUC: Mucin; TLR: Toll-
Like Receptor; MPLA: Monophophoryl Lipid A; ISCOM: Immune stimulating complex; IM: intramuscular 
 
Table 5: The most promising cancer vaccines involving the TC administration route.   
Vaccine Adjuvant Administration route 
Traget cancer 
type 
Clinical 
trial Study outcome REF  
CDX-1401 : full 
length NY-ESO-1- 
protein, fused to 
anti DEC-2015 mAb 
Resiquimod (TLR 
7/8 agonist)  
Or 
Poly ICLC (TLR 3 
agonist) 
Various 
combinations 
of TC and SC 
routes  
melanoma, 
sarcoma, 
ovarian 
cancer and 
others 
Phase I - NY-ESO-1-specific cellular 
immunity of 56% of the 
patients 
- Disease stabilization in 
13/56 patients, and 
occasional disease 
regression 
[93]
Full length NY-ESO-
1 protein 
 
Imiquimod (TLR 
7 agonist) 
Protein (ID) and  
imiquimod (TC) 
Melanoma Phase I - NY-ESO-1 specific antibodies
- Absence of CD8+ response 
[91]
Resiquimod (TLR 
7/8 agonist) and 
montanide  
montanide-
emulsfied 
protein (ID) and 
resiquimod (TC) 
Melanoma Phase II - NY-ESO-1 specific antibodies 
in all subjects 
- Specific CD4+ T cells and 
CD8+ T cells (in 3/12 
subjects) 
[90]
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Tumor-derived 
peptides/DMSO 
Absence of 
adjuvant 
molecule- Tape 
tripping for skin-
barrier 
disruption 
TC Melanoma Phase I - Extension of overall survival [94]
mAb: monoclonal antibody; TLR: Toll-Like Receptor, Poly-ICLC: Polyinosinic-Polycytidylic acid with 
Polylysine and Carboxymethylcellulose; TC: transcutaneous; SC: subcutaneous; ID: intradermal, DMSO: 
Dimethylsulfoxide 
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